Innate Pharma SA Class A
No trades
No trades
Fundamentals and stats
EPS and revenue snapshot
In the last semiannual, the company reported −0.30 EUR per share, beating the −0.30 EUR estimate by 0.00%. Revenue for the same period reached 4.14 M EUR, despite the estimate of 4.90 M EUR. For the next semiannual, analysts expect −0.31 EUR in earnings per share and 3.99 M EUR in revenue.
Next report date—
Report period—
EPS estimate—
Revenue estimate—
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise